Breaking News

DSM, Eisai In Master Supply Pact

DSM will produce eribulin mesylate for the U.S. market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Pharmaceutical Products has signed a three-year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, for the production of sterile products, including eribulin mesylate and other developmental drugs. DSM will supply eribulin mesylate for the U.S. market with commercial production expected to begin in early 2013. DSM will manufacture the product at its finished dosage facility in Greenville, NC. Financial details were not disclosed.   Laura Parks, president of DSM Pharmaceuti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters